Boryung Pharmaceutical
VC Fund
Seoul, South Korea
Boryung Pharmaceutical is a VC fund in Seoul focused on Medical and Health Care. Boryung, originally involved in pharmaceutical wholesale, transitioned into pharmaceutical manufacturing in 1963. Instead of simply being a drug manufacturer, the company decided to invest in the development of essential medicines for patients. This strategic shift paved the way for sustained growth in the pharmaceutical industry. Notably, in March2011, Boryung achieved a significant milestone by introducing "Kanarb," the first ARB (Angiotensin II Receptor Blocker) antihypertensive medication in South Korea.Looking ahead, in April 2022, Boryung is set to host the inaugural Care in Space (CIS) Challenge. This initiative demonstrates the company's commitment to exploring new horizons and aligns with its mission to become an indispensable contributor to human health in the era of space exploration. By embarking on this challenge, Boryung aims to discover fresh opportunities that can further its role in advancing human health, especially as technological advancements open up new frontiers.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Boryung Pharmaceutical invests in
Stages Boryung Pharmaceutical invests in
Countries Boryung Pharmaceutical invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jay Jung Gyun Kim
|
|||
Investment Focus
Industry
- Medical 2 (33%)
- Health Care 2 (33%)
- Biotechnology 2 (33%)
- Software 1 (17%)
- Aerospace 1 (17%)
Stage
- Seed 2 (33%)
- Pre-Seed 1 (17%)
- Series C 1 (17%)
- Funding Round 1 (17%)
Country
- United States 2 (33%)
- Luxembourg 1 (17%)
- United Kingdom 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jay Jung Gyun Kim
CEO
|
CEO | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
LambdaVision
|
LambdaVision, Inc. is commercializing a retinal implant to restore vision for the millions of patients suffering from retinitis pigmentosa (RP) and age-related macular degeneration (AMD). | $7M / Seed / Nov 05, 2025 | |
Exobiosphere
|
Exobiosphere is a cutting-edge company operating at the intersection of space exploration and biotechnology. | $2.2M / Seed / Apr 04, 2025 | |
|
LambdaVision
|
LambdaVision, Inc. is commercializing a retinal implant to restore vision for the millions of patients suffering from retinitis pigmentosa (RP) and age-related macular degeneration (AMD). | May 29, 2024 | |
|
LambdaVision
|
LambdaVision, Inc. is commercializing a retinal implant to restore vision for the millions of patients suffering from retinitis pigmentosa (RP) and age-related macular degeneration (AMD). | Seed / May 29, 2024 | |
Axiom Space
|
Axiom Space is a space infrastructure company that develops commercial human spaceflight services and orbital platforms. It organizes private astronaut missions to the International Space Station, providing training, mission planning, and in-orbit support. The company is also building commercial space station modules intended to operateindependently in low Earth orbit. In addition, it develops spacesuits and spaceflight systems to support government and commercial customers. Its activities integrate mission operations, engineering, and space hardware development to expand access to space. | $350M / Series C / Aug 21, 2023 | |
MyelinZ
|
MyelinZ Group is redefining brain and body health with AI-driven neurotechnology. As the first Virtual Gym for the Brain, the company's three groundbreaking products (BodyMirror, SpaceMirror, and R-MMS) fuse neuroscience, AI, and gaming to unlock human potential on Earth and beyond. | $1.2M / Pre-Seed / Jan 26, 2023 |
Co-Investors
Aurelia Foundry
3 deals together
E2MC Ventures
3 deals together
Aljazira Capital
1 deal together
Alumni Ventures
1 deal together
Chenel Capital Partners
1 deal together
Expansion Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Boryung Pharmaceutical invest in?
Boryung Pharmaceutical invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Pre-Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Boryung Pharmaceutical?
Public channels for Boryung Pharmaceutical include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Boryung Pharmaceutical?
The team at Boryung Pharmaceutical includes Jay Jung Gyun Kim (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
